Acute Myeloid Leukemia Clinical Trial

Feasibility of Telehealth Palliative Care and Digital Symptom Monitoring for Patients With Acute Myeloid Leukemia

Summary

AML is the most common leukemia diagnosed in adults. In spite of recent low-intensity therapies that have improved outcomes for older AML patients, AML remains associated with poor prognosis as well as high symptom burden. While the benefits of early palliative care as well as electronic PROs have been well-described in the oncology population, neither have been well-studied in the AML population, and have never been studied in combination. We propose a prospective, single-center, single-arm trial to evaluate the feasibility of a virtually-mediated supportive care model utilizing both electronic PROs and palliative care for patients with AML being treated with low-intensity therapy.

AIM1: is to evaluate and describe the feasibility of implementing early specialty palliative care referrals carried out via telehealth/video-based modalities in combination with digital symptom monitoring for patients recently diagnosed with acute myeloid leukemia (AML) and starting low intensity induction therapy.

AIM2: study the differences in health-related quality-of-life (HRQoL) metrics using patient-reported outcomes (PROs) in patients recently diagnosed with AML and starting low intensity induction therapy who receive early referral to telehealth/video-based palliative care visits compared to standard care.

AIM3: to explore the patient experience of patients with AML on low-intensity therapy, capture rates of advance care planning, hospice utilization, and hospital utilization.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients being treated for a diagnosis of acute myeloid leukemia at Stanford Cancer Center
Patients determined to be candidates for low intensity induction therapy (not requiring hospitalization to administer treatment) by their leukemia physician
Estimated life expectancy of 6 months
Functional status at the level of at least being capable of limited self-care, confined to chair or bed for half the day or better
Access to smartphone, tablet, or computer with capability to utilize a symptom tracking application

Exclusion Criteria:

Relapsed or refractory AML
Patients who have established care with palliative care previously
Non-English-speaking, as the Noona application is developed in the English language

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

40

Study ID:

NCT04885127

Recruitment Status:

Recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford University
Palo Alto California, 94304, United States More Info
Irena Tan, MD
Contact
[email protected]
Gabriel Mannis, MD
Principal Investigator
Irena Tan, MD
Sub-Investigator
Kavitha Ramchandran, MD
Sub-Investigator

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Estimated Enrollment:

40

Study ID:

NCT04885127

Recruitment Status:

Recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.